Publikacje

Publikacje i komunikaty zjazdowe

Publikacje własne Zakładu od roku 2007

  3. Hartman ML, Sztiller-Sikorska M, Czyz M: Synergistic activity of S63845 and parthenolide to overcome acquired resistance to MEK1/2 inhibitor in melanoma cells: Mechanisms and therapeutic potential (2025) Biomed Pharmacother. doi: 10.1016/j.biopha.2025.118183
  4. Chrzan N, Hartman ML: Copper in melanoma: at the crossroad of protumorigenic and anticancer roles (2025) Redox Biology. doi: 10.1016/j.redox.2025.103552
  5. Wawrzyniak P, Hartman ML: Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors (2025) Molecular Cancer. doi: 10.1186/s12943-025-02294-x.
  6. Wozniak M, Czyz M: Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities (2025) Ther Adv Med Oncol. 7:17:17588359241306026.
  7. Hartman ML: Tipping the balance of cell death: alternative splicing as a source of MCL-1S in cancer (2024) Cell Death Dis. 18;15(12):917.
  8. Gajos-Michniewicz A, Czyz M: Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges (2024) Int J Mol Sci. 28;25(23):12804
  9. Gajos-Michniewicz A, Czyz M: WNT/b-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. (2023) Genes Dis 11(2):727-746.
  10. Wozniak M, Czyz M: lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma. (2023) Front Mol Biosci 10:1170026.
  11. Koziej P, Kluszczynska K, Hartman ML, Czyz M: Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge. (2023) Int J Mol Sci 24(9):7891.
  12. Hartman ML, Czyz M: BCL-G: 20 years of research on a non-typical protein from the BCL-2 family. (2023) Cell Death Differ 30(6):1437-1446.
  13. Hartman ML, Koziej P, Kluszczyńska K, Czyz M: Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal. (2023) Cancers (Basel) 15(19):4799.
  14. Kluszczynska K, Czyz M: Extracellular Vesicles-Based Cell-Cell Communication in Melanoma: New Perspectives in Diagnostics and Therapy. (2023) Int J Mol Sci. 24(2):965.
  15. Wozniak M, Czyz M: The Functional Role of Long Non-Coding RNAs in Melanoma. (2021) Cancers 13(19): 4848.
  16. Osrodek M, Wozniak M: Targeting Genome Stability in Melanoma-A New Approach to an Old Field. (2021)  Int J Mol Sci 22(7):3485.
  17. Hartman ML, Gajos-Michniewicz A, Talaj JA, Mielczarek-Lewandowska A, Czyz M: BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF V600E melanoma cells. (2021) Cancer Lett. 499:122-136
  18. Osrodek M, Rozanski M, Czyz M: Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma. (2020) Cells. Cancer Manag Res. 12: 7231-50.
  19. Sztiller-Sikorska M , Czyz M: Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies. (2020) Pharmaceuticals (Basel) 13(8):194.
  20. Gajos-Michniewicz A, Czyz M: WNT Signaling in Melanoma. (2020) Int. J. Mol. Sci.  21: 4852.
  21. Hartman ML, Rogut M, Mielczarek-Lewandowska A, Wozniak M, Czyz ME: 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines. (2020) Int J Mol Sci 21(11):E374
  22. Hartman ML, Czyż ME: BCL-w: apoptotic and non-apoptotic role in health and disease. (2020) Cell Death Dis 11(4):260
  23. Hartman ML: Non-Apoptotic Cell Death Signaling Pathways in Melanoma, w: International Journal of Molecular Sciences. (2020) Int J Mol Sci 21(8):2980
  24. Hartman ML, Sztiller-Sikorska M, Gajos-Michniewicz A, Czyz M: Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity. (2020) Cells 9: 142
  25. Mielczarek-Lewandowska A, Hartman ML, Czyz M: Inhibitors of HSP90 in melanoma. (2019) Apoptosis
  26. Hartman ML, Czyz M: TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells. (2019) Archives of Dermatological Research
  27. Osrodek M, Hartman ML, Czyz M: Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro. (2019) International Journal of Medical Sciences 20: 4203
  28. Czyz M, Sztiller-Sikorska M, Gajos-Michniewicz A, Marta Osrodek M, Mariusz L. Hartman ML: Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program. (2019) Journal of Oncology 2019: 1697913.
  29. Mielczarek-Lewandowska A, Sztiller-Sikorska M, Osrodek M, Czyz M, Hartman ML: 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF(V600E) inhibitors in melanoma cells of different genetic subtypes. (2019) Apoptosis 24: 596-611.
  30. Czyz M: Fibroblast Growth Factor Receptor Signaling in Skin Cancers.(2019) Cells 8: E540
  31. Gajos-Michniewicz A, Czyz M: Role of miRNAs in Melanoma Metastasis.(2019) Cancers(Basel) 11: E326
  32. Hartman ML, Sztiller-Sikorska M, Czyz M: Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. (2019) Molecular Carcinogenesis 58: 588-602  
  33. Czyz M: HGF/c-MET Signaling in Melanocytes and Melanoma. (2018) International Journal of Molecular Sciences 19: E3844.
  34. Zalesna I, Osrodek M, Hartman ML, Rozanski M, Sztiller-Sikorska M, Niewinna K, Nejc D, Czyz M: Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro. (2017) PLoS One 12: e0183498
  35. Hartman ML, Różański M, Ośrodek M, Zaleśna I, Czyż M: Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells. (2017) Laboratory Investigation 97: 217-227
  36. Zaleśna I, Ośrodek M, Hartman MŁ, Różański M, Sztiller-Sikorska M, Niewinna K, Nejc D, Czyż M: Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro.(2017) PlosOne 12: e0183498
  37. Hartman MŁ, Talar B, Sztiller-Sikorska M, Nejc D, Czyż M: Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. (2016) Oncotarget 7: 9026-9040
  38. Gajos-Michniewicz A, Czyż M: Modulation of WNT/β-catenin pathway in melanoma by biologically active components derived from plants. (2016) Fitoterapia 109: 283-292
  39. Zaleśna I, Hartman MŁ, Czyż M: Znaczenie mutacji BRAF dla progresji i terapii czerniaka, raka brodawkowatego tarczycy i raka jelita grubego. (2016) Postępy Higieny Medycyny Doświadczalnej 70: 471-488
  40. Talar B, Gajos-Michniewicz A, Talar M, Chouaib S, Czyż M: Pentoxifylline inhibits WNT sigmalling in β-cateninhigh patient-derived melanoma cell populations. (2016) PlosOne 11: e0158275
  41. Woźniak M, Mielczarek A, Czyż M: miRNAs in melanoma: tumor suppressors and oncogenes with prognostic potential. (2016) Current Medicinal Chemistry 23: 1-18
  42. Woźniak M, Sztiller-Sikorska M, Czyż M: Diminution of miR-340-5p levels is responsible for increased expression of ABCB5 in melanoma cells under oxygen-deprived conditions. (2015) Experimental and Molecular Pathology 99: 707-716
  43. Woźniak M, Sztiller-Sikorska M, Czyż M: Expression of miRNAs as important element of melanoma cell plasticity in response to microenvironment stimuli. (2015) Anticancer Research 35: 2747-2758
  44. Hartman ML, Talar B, Gajos-Michniewicz A, Czyż M: MCL-1, BCL-XL and MITF are diversely employed in adaptive response of melanoma cells to changes in microenvironment. (2015) Plos One 10: e0128796
  45. Sztiller-Sikorska M, Hartman ML, Talar B, Jakubowska J, Zaleśna I, Czyż M: Phenotypic diversity of patient-derived melanoma populations in stem cell medium. (2015) Laboratory Investigation doi:10.1038/labinvest.2015.48
  46. Hartman ML, Czyż M: Pro-survival role of MITF in melanoma. (2015) Journal of Investigative Dermatology 135: 352-358
  47. Hartman ML, Czyż M: MITF in melanoma: mechanisms behind its expression and activity. (2015) Cellular and Molecular Life Sciences 72: 1249-1260
  48. Sztiller-Sikorska M, Koprowska K, Majchrzak K, Hartman M, Czyż M: Natural compounds’ activity against cancer stem-like or fast-cycling melanoma cells. (2014) PLoS One 9: e90783
  49. Hartman MŁ, Talar B, Noman MZ, Gajos-Michniewicz A, Chouaib S, Czyż M: Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype. (2014) PLoS One 9: e95157
  50. Gajos-Michniewicz A, Duechler M, Czyż M: MiRNA in melanoma-derived exosomes. (2014) Cancer Letters 347: 29-37
  51. Czyż M, Koprowska K, Sztiller-Sikorska M: Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. (2013) Cancer Biology and Therapy 14: 135-145
  52. Hartman MŁ, Czyż M: Anti-apoptotic proteins on guard of melanoma cell survival. (2013) Cancer Letters 331: 24-34
  53. Koprowska K, Hartman MŁ, Sztiller-Sikorska M, Czyż ME: Parthenolide enhances dacarbazine activity against melanoma cells. (2013) Anticancer Drugs 24: 835-845
  54. Woźniak M: microRNA in the control of stem-like phenotype of cancer cells. (2013) Central European Journal of Biology 8: 931-942
  55. Woźniak M, Szuławska-Mroczek A, Hartman MŁ, Nejc D, Czyż M: Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells. (2013) Anticancer Research 33: 3205-3212
  56. Talar B, Czyż M: Rola szlaków sygnałowych TGF-β w nowotworach. (2013) Postępy Higieny i Medycyny Doświadczalnej 67: 1008-1017
  57. Hartman MŁ, Czyż M: Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy. (2012) Anti-Cancer Agents in Medicinal Chemistry 12: 966-981
  58. Sztiller-Sikorska M, Koprowska K, Jakubowska J, Zaleśna I, Stasiak M, Duechler M, Czyż ME: Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment. (2012) Melanoma Research 22: 215-224
  59. Hartman MŁ, Czyż M: Mimetyki BH3 jako terapia wspomagająca konwencjonalne leki przeciwnowotworowe. (2012) Postępy Higieny i Medycyny Doświadczalnej 66: 67–77
  60. Wilczyński J, Duechler M, Czyż M: Targeting NF-κB and HIF-1 pathways for the treatment of cancer: Part I. (2011) Archivum Immunologiae et Therapiae Experimentalis 59: 289-299
  61. Wilczyński J, Duechler M, Czyż M: Targeting NF-κB and HIF-1 pathways for the treatment of cancer: Part II. (2011) Archivum Immunologiae et Therapiae Experimentalis 59: 301-307
  62. Koprowska K, Czyż M: Dakarbazyna jako lek przeciwczerniakowy i referencyjny dla nowych programów terapeutycznych. (2011) Postępy Higieny i Medycyny Doświadczalnej 65: 734-751
  63. Czyż M, Lesiak-Mieczkowska K, Koprowska K, Szuławska-Mroczek A, Woźniak M: Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. (2010) British Journal of Pharmacology 160: 1144-1157
  64. Lesiak K, Koprowska K, Zaleśna I, Nejc D, Düchler M, Czyż M: Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro. (2010) Melanoma Research 20: 21-34
  65. Koprowska K, Czyż M: Molekularne mechanizmy działania partenolidu – stary lek z nową twarzą. (2010) Postępy Higieny i Medycyny Doświadczalnej 64: 100-114
  66. Sztiller-Sikorska M, Jakubowska J, Woźniak M, Stasiak M, Czyż M: A non-apoptotic function of caspase-3 in pharmacologically-induced differentiation of K562 cells. (2009) British Journal of Pharmacology 157: 1451-1462
  67. Czyż M, Jakubowska J, Sztiller-Sikorska M: STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562. (2008) Biochemical Pharmacology 75: 1761-1773
  68. Jakubowska J, Wasowska-Łukawska M, Czyż M: STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. (2008) European Journal of Pharmacology 596: 41-49
  69. Woźniak M, Czyż M: Mimetyki dysmutazy ponadtlenkowej – potencjalne zastosowania kliniczne. (2008) Postępy Higieny i Medycyny Doświadczalnej 62: 613-624
  70. Jakubowska J, Stasiak M, Szuławska A, Bednarek A, Czyż M: Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562. (2007) Acta Biochimica Polonica 54: 839-846
  71. Lesiak K, Sztiller-Sikorska M, Czyż M: Czynniki transkrypcyjne w powstawaniu i progresji czerniaka. (2007) Postępy Higieny i Medycyny Doświadczalnej 61: 576-595
  72. Szuławska A, Arkusińska J, Czyż M: Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives. (2007) Biochemical Pharmacology 73: 175-184

Publikacje we współpracy od roku 2007

  1. Bojarska J, Breza M, Remko M, Czyz M, Gajos-Michniewicz A, Zimecki M, Kaczmarek K, Madura ID, Wojciechowski JM, Wolf WM: Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond. (2022) Int J Mol Sci. 23(13):7173. https://pubmed.ncbi.nlm.nih.gov/35806175/
  2. Kluszczyńska K, Pęczek Ł, Różański A, Czernek L, Düchler M: U6/miR-211 expression ratio as a purity parameter for HEK293 cell-derived exosomes. (2022) Acta Biochim Pol. 69(2):409-415.
  3. Zhang L,  Geng X, Wang F, Tang J, Ichida Y, Sharma A, Jin S, Chen M, Tang M, Pozo FM, Wang W, Wang J, Wozniak M, Guo X, Miyagi M, Jin F, Xu Y, Yao X, Zhang Y: 53BP1 regulates heterochromatin through liquid phase separation. (2022) Nature Commun. 13: 360.
  4. Madej E , Ryszawy D, Brożyna AA, Czyz M, Czyz J, Wolnicka-Glubisz A: Deciphering the Functional Role of RIPK4 in Melanoma. (2021) Int J Mol Sci 22(21):11504
  5. Brambilla D, Sola L, Ferretti AM, Chiodi E, Zarovni N, Fortunato D, Criscuoli M, Dolo V, Giusti I, Murdica V, Kluszczyńska K, Czernek L, Düchler M, Vago R, Chiari M: EV Separation: Release of Intact Extracellular Vesicles Immunocaptured on Magnetic Particles. (2021) Anal Chem 93(13):5476-5483.
  6. Xu Y-J , Khan S, Didier AC , Woźniak M , Liu Y, Singh A , Nakamura TM: A tel2 Mutation That Destabilizes the Tel2-Tti1-Tti2 Complex Eliminates Rad3 ATR Kinase Signaling in the DNA Replication Checkpoint and Leads to Telomere Shortening in Fission Yeast. (2019) Mol Cell Biol  39(20):e00175-19
  7. Düchler M, Czernek L, Peczek L, Cypryk W, Sztiller-Sikorska M, Czyz M: Melanoma-Derived Extracellular Vesicles Bear the Potential for the Induction of Antigen-Specific Tolerance. (2019) Cells 8: E665
  8. Wozniak M, Peczek L, Czernek L, Düchler M: Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions. (2017) Anticancer Research 37: 6779-6789
  9. Pastuszko A, Majchrzak K, Czyż M, Kupcewicz B, Budzisz E: The synthesis, lipophilicity and cytotoxic effect of new ruthenium(II) arene complex with chrome derivatives. (2016) Journal of Inorganic Biochemistry 159: 133-141 (Zakład Chemii Surowców Kosmetycznych UM w Łodzi)
  10. Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Śliwiński T, Skorski T: PARP1 inhibitor olaprib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. (2016) Oncotarget 7: 75551-75560
  11. Grażul M, Sigel R, Maake C, Besic-Gyenge E, Lorenz I-P, Meyer P, Czyż M, Budzisz E: Synthesis, structure, physico-chemical and biological properties of metal(II) complexes with 5-amino-8-methyl-4H-benzopyran-4-one. (2014) Polyhedron 67: 136-144 (Zakład Chemii Surowców Kosmetycznych UM w Łodzi)
  12. Duechler M, Pęczek Ł, Żuk K, Zaleśna I, Jeziorski A, Czyż M: The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. (2014) Immunobiology 219: 158-165 (Centrum Badań Molekularnych i Makromolekularnych PAN)
  13. Grażul M, Besic-Gyenge E, Maake C, Ciołkowski M, Czyż M, Sigel RK, Budzisz E: Synthesis, physico-chemical properties and biological analysis of newly obtained copper(II) complexes with pyrazole derivatives. (2014) Journal of Inorganic Biochemistry 135: 68-76 (Zakład Chemii Surowców Kosmetycznych UM w Łodzi)
  14. Szubert M, Suzin J, Duechler M, Szuławska A, Czyż M, Kowalczyk-Amico K: Evaluation of selected angiogenic and inflammatory markers in endometriosis before and after danazol treatment. (2014) Reproduction, Fertility and Development 26: 414-420 (Klinika Ginekologii Operacyjnej i Onkologicznej UM w Łodzi)
  15. Kupcewicz B, Sobiesiak K, Malinowska K, Koprowska K, Czyż M, Keppler B, Budzisz E: Copper(II) complexes with derivatives of pyrazole as potential antioxidant enzyme mimics. (2013) Medicinal Chemistry Research 22: 2395-2402 (Zakład Chemii Surowców Kosmetycznych UM w Łodzi)
  16. Pastuszko A, Niewinna K, Czyż M, Jóźwiak A, Małecka M, Budzisz E: Synthesis, X-ray structure, electrochemical properties and cytotoxic effects of new arene ruthenium(II) complexes. (2013) Journal of Organometallic Chemistry 745-746: 64-70 (Zakład Chemii Surowców Kosmetycznych UM w Łodzi)
  17. Szuławska-Mroczek A, Szumilak M, Szczesio M, Olczak A, Nazarski R B, Lewgowd W, Czyż M, Stańczak A: Synthesis and biological evaluation of new bischromone derivatives with antiproliferative activity. (2013) Archiv der Pharmazie – Chemistry in Life Sciences 346: 34-43 (Zakład Farmacji Szpitalnej UM w Łodzi)
  18. Grażul M, Kufelnicki A, Woźniczka M, Lorenz I-P, Mayer P, Jóźwiak A, Czyż M, Budzisz E: Synthesis, structure, electrochemical properties, cytotoxic effects and antioxidant activity of 5-amino-8-methyl-4H-benzopyran-4-one and its copper(II) complexes. (2012) Polyhedron 31: 150-158 (Zakład Chemii Surowców Kosmetycznych UM w Łodzi)
  19. Luzak B, Boncler M, Rywaniak J, Wilk R, Stańczyk L, Czyż M, Rysz J, Watała C: The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients. (2011) European Journal of Pharmacology 658: 91-97 (Zakład Zaburzeń Krzepnięcia Krwi UM w Łodzi)
  20. Sztiller-Sikorska M, Heyduk E, Heyduk T: Promoter spacer DNA plays an active role in integrating the functional consequences of RNA polymerase contacts with – 10 and – 35 promoter elements. (2011) Biophysical Chemistry 159: 73-81 (Zakład Biochemii i Biologii Molekularnej, Uniwersytet w St. Louis, USA)
  21. Szumilak M, Szuławska-Mroczek A, Koprowska K, Stasiak M, Lewgowd W, Stańczak A, Czyż M: Synthesis and in vitro biological evalution of new polyamine conjugates as potential anticancer drugs. (2010) European Journal of Medicinal Chemistry 45: 5744-5751 (Zakład Farmacji Szpitalnej UM w Łodzi)
  22. Wirth S, Wallek AU, Zernickel A, Feil F, Sztiller-Sikorska M, Lesiak-Mieczkowska K, Brauchle C, Lorenz I-P, Czyż M: Tautomerization of 2-nitroso-N-arylanilines by coordination as N,N'-chelate ligands to rhenium(I) complexes and the anticancer activity of newly synthesized oximine rhenium(I) complexes against human melanoma and leukemia cells in vitro. (2010) Journal of Inorganic Biochemistry 104: 774-789 (Zakład Chemii i Biochemii, Uniwersytet w Monachium, Niemcy)
  23. Miernicka M, Szuławska A, Czyż M, Lorenz I-P, Mayer P, Karwowski B, Budzisz E: Cytotoxic effect, differentiation, inhibition of growth and theoretical calculations of an N,N-donor ligands and its platinum(II), palladium(II) and copper(II) complexes. (2008) Journal of Inorganic Biochemistry 102: 157-165 (Zakład Chemii Surowców Kosmetycznych UM w Łodzi)
  24. Duechler M, Stańczyk M, Czyż M, Stępnik M: Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells. (2008) Cancer Chemother Pharmacology 61: 727-737 (Instytut Medycyny Pracy w Łodzi)
  25. Boncler M, Gresner P, Nocun M, Rywaniak J, Dolnik M, Rysz J, Wilk R, Czyż M, Markuszewski L, Banach M, Watała C: Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. (2007) Biochimica Biophysica Acta 1770: 1651-1659 (Zakład Zaburzeń Krzepnięcia Krwi UM w Łodzi)
  26. Pastwa E, Somiari SB, Czyz M, Somiari RI: Proteomics in human cancer research. (2007) Proteomics Clinical Application 1: 4-17 (Zakład Genetyki Molekularnej UM w Łodzi)

KONFERENCJE od roku 2007

  1. Chrzan N, Suwara Ja, Sztiller-Sikorska M, Wawrzyniak P, Czyz M, Hartman ML: Metabolic phenotype determines melanoma cell sensitivity to copper – delivering agents. Translational Research: Innovation Born of Need, 19-21th November 2025, Prague, Czech Republic.
  2. Wawrzyniak P, Sztiller-Sikorska M, Sobolewska W, Chrzan N, Czyz M, Hartman ML: IFN-γ drives phenotypic changes in melanoma cells and potentiates cell sensitivity to GLUT1 inhibition. Translational Research: Innovation Born of Need, 19-21th November 2025, Prague, Czech Republic.
  3. Chrzan N, Suwara J, Sztiller-Sikorska M, Czyz M, Hartman ML: The role of copper in melanoma – potential application of copper-chelating and copper-delivering agents. 10th International Doctoral Students’ Conference in Life Sciences BioOpen, 15-16th May 2025, Łódź.
  4. Wawrzyniak P, Sztiller-Sikorska M, Sobolewska W, Czyż M, Hartman ML: IFN-γ in tumor microenvironment as a factor causing changes in melanoma cell phenotype. 10th International Doctoral Students’ Conference in Life Sciences BioOpen, 15-16th May 2025, Łódź.
  5. Tęcza P, Kędzierska M, Kurczewska M, Potemski P: Czy lokalizacja czerniaka BRAF (+) w skórze gruczołu piersiowego wpływa na rokowanie i postępowanie terapeutyczne? XXIII Kongres Polskiego Towarzystwa Onkologii Klinicznej, Kraków, Polska, 27–29 August 2020
  6. Hartman ML, Gajos-Michniewicz A, Talaj J, Mielczarek-Lewandowska A, Kluszczynska K, Tecza P, Czyz M: S63845, a selective inhibitor of MCL-1, cooperates with encorafenib in induction of apoptosis in BRAFV600E melanoma cells. 10th World Congress of Melanoma in conjunction with 17th EADO Congress, Interactive virtual meeting, 15-17 April 2021
  7. Sztiller-Sikorska M, Hartman ML, Gajos-Michniewicz A, Tecza P, Czyz M: Mapping the hallmarks of melanoma resistance to vemurafenib or trametinib revealed genetic and non-genetic patient- and drug-specific alterations and a high phenotypic plasticity. 10th World Congress of Melanoma in conjunction with 17th EADO Congress, Interactive virtual meeting, 15-17 April 2021
  8. Hartman ML: „Modulation of the activity of BCL-2 proteins as a potential therapeutic
    target in drug-naive and targeted therapy-resistant melanoma.     Webinar „"Molecular basis of cancer pathophysiology and anticancer therapies”, Lodz Division of the Polish Biochemical Society, 25 April 2024
  9. Hartman ML, Gajos-Michniewicz A, Talaj J.A., Mielczarek-Lewandowska A, Czyz M Encorafenib alters melanoma cell proximity to the apoptotic threshold – implications for complementary therapeutic strategy using selective BH3 mimetics. XXIV Gliwice Scientific Meetings, Gliwice, Poland, 20-21 November 2020
  10. Czyz M, Osrodek M, Gajos-Michniewicz A, Sztiller-Sikorska M Oxygen concentration contributes to phenotypic heterogeneity of melanoma during adaptive response to targeted therapeutics. Nature Conference on Cellular Metabolism; Xiamen, China, 8-11 April 2019
  11. Osrodek M, Hartman ML, Czyz M Response of melanoma cells to vemurafenib and trametinib at the level of metabolic phenotype. Nature Conference on Cellular Metabolism; Xiamen, China, 8-11 April 2019
  12. Rogut ME, Hartman ML, Mielczarek-Lewandowska A, Sztiller-Sikorska M, Gajos-Michniewicz A, Czyz M The effect of 17-aminogeldanamycin on NF-κB activity in patient-derived melanoma cell lines. 11th International Conference of Contemporary Oncology, Poznań, Poland 13-15 March 2019
  13. Mielczarek-Lewandowska A, Hartman ML, Sztiller-Sikorska M, Osrodek M, Gajos-Michniewicz A, Czyz M 17-aminogeldanamycin inhibits cytoprotective UPR pathways and cooperates with inhibitors of the MAPK signaling cascade in apoptosis induction. Melanoma: from biology to target; Houston, USA 15-18 January 2019
  14. Rogut M, Zietara M, Hartman ML, Czyz M, Wilczynski J, Szubert M Is it possible to diagnose endometriosis at the level of endometrium? Gynecological Endocrinology: The 18th World Congress; Florence, Italy, 7-10 March 2018
    Czyż M (Speaker) Feverfew and parthenolide – phytochemical, pharmacological and clinical evidence. A Scientific Workshop; Vienna, Austria, 16 November 2017
  15. Hartman ML, Sztiller-Sikorska M, Ośrodek M, Zaleśna I, Mielczarek A, Czyż M V600EBRAF melanoma cell response to vemurafenib and trametinib is not affected by exogenous growth factors bFGF, EGF and HGF in vitro. 9th World Congress of Melanoma; Brisbane, Australia; 18-21 October 2017
  16. Ośrodek M, Hartman ML, Różański M,  Sztiller-Sikorska M, Niewinna K, Czyż M Composition or lack of exogenous growth factors do not influence viability and phenotype of drug- naïve V600EBRAF melanoma cells but it might be crucial for drug-resistant cells. 9th World Congress of Melanoma; Brisbane, Australia; 18-21 October 2017
  17. Hartman M, Gajos-Michniewicz A, Talar B, Czyż M MCL-1 protects patient-derived melanoma cells from death during rapid changes in microenvironment. EACR Conference Series: A Matter of Life or Death; Mechanisms and Relevance of Cell Death for Cancer Biology and Treatment  2016; Amsterdam, Netherlands; 28-30 January 2016
  18. Zaleśna I, Różański M, Sztiller-Sikorska M, Hartman M, Czyż M: Melanoma cell plasticity in response to diverse growth factors. EMBL Symposium: Tumor Microenvironment and Signalling 2016; Heidelberg, Germany; 03-06 April 2016
  19. Ośrodek M, Hartman M, Różański M, Zaleśna I, Talar B, Niewinna K, Sztiller-Sikorska M, Nowicki J, Nejc D, Czyż M: Response of patient-derived melanoma cells to different growth factors. 2nd EACR Conference: Goodbye Flat Biology; Models, Mechanisms and Microenvironment 2016; Berlin, Germany; 02-05 October 2016
  20. Hartman ML, Stiller-Sikorska M, Mielczarek A, Talar B, Nejc D, Czyż M: Natural compound parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. XXth Gliwice Scientific Meetings 2016; Gliwice, Poland; 18-19 November 2016
  21. Talar B, Gajos-Michniewicz A, Czyż M: Modulation of canonical WNT pathway In patent-derived melanoma cell lines by natura compounds. Conference for Young Scientists 2015; Kijów, Ukraina; 21-25 September 2015
  22. Gajos-Michniewicz A, Talar B, Hartman ML, Czyż M: Microenvironment-driven alterations of invasive potential of patent-derived melanoma cells. Conference for Young Scientists 2015; Kijów, Ukraina; 21-25 September 2015
  23. Hartman ML, Sztiller-Sikorska M, Talar B, Gajos-Michniewicz A, Czyż M: Immediate and long-term molecular response of melanoma cells to changes in microenvironment. XVIIIth Gliwice Scientific Meetings 2014; Gliwice, 21-22 November 2014
  24. Czyż M, Majchrzak K, Koprowska K, Hartman M, Sztiller-Sikorska M: Short- and long-term effects of natural compounds on melanoma cells derived from surgical specimens. Cell Death Signaling In Cancer and the Immune System; Guaruja, Sao Paulo, Brazil; 28 October – 2 November 2014
  25. Hartman M, Talar B, Gajos-Michniewicz A, Czyż M: Diverse pro-survival responses of heterogeneous melanoma cell lines to changes in microenvironment. Cell Death Signaling In Cancer and the Immune System; Guaruja, Sao Paulo, Brazil; 28 October – 2 November 2014
  26. Toma M, Gajos-Michniewicz A, Majchrzak K, Wieteska Ł, Szemraj J, Czyż M, Skorski T, Śliwiński T: Personalized synthetic lethality induced by targeting RAD52 and PARP1 in melanomas. The Ninth International Conference of Anticancer Research; Sithonia, Greece; 6-10 October 2014
  27. Woźniak M, Gajos-Michniewicz A, Sztiller-Sikorska M, Pęczek Ł, Duechler M, Czyż M: MiRNAs from exosomes released by melanoma cells grown in 3-dimensional manner. Tissue Models and Drug Screening Conference; Berlin; 6-7 May 2014
  28. Sztiller-Sikorska M, Majchrzak K, Hartman M, Czyż M: Short- and long-term effects of natural compounds on melanoma cells grown in anchorage-independent manner. Tissue Models and Drug Screening Conference; Berlin; 6-7 May 2014
  29. Czyż M (Invited Speaker): Heterogeneity of melanospheres: therapeutic implications. XVII Gliwice Scientific Meetings; Gliwice; 15-16 November 2013
  30. Hartman MŁ, Sztiller-Sikorska M, Talar B, Chouaib S, Czyż M: Transcriptome profiles of melanospheres and monolayers derived from nodular melanoma specimens. XVII Gliwice Scientific Meetings; Gliwice; 15-16 November 2013
  31. Talar B, Sztiller-Sikorska M, Gajos-Michniewicz A,  Koprowska K, Czyż M: Phenotypic heterogeneity and plasticity of cells in melanospheres derived from nodular melanoma specimens. XVII Gliwice Scientific Meetings; Gliwice; 15-16 November 2013
  32. Woźniak M, Sztiller-Sikorska M, Czyż M: Differential expression of microRNA in diverse phenotypes of melanoma cells. XVII Gliwice Scientific Meetings; Gliwice; 15-16 November 2013
  33. Czyż M, Hartman M, Talar B, Gajos-Michniewicz A, Zaleśna I, Sztiller-Sikorska M, Zaeem N, Salem C: Melanoma morphologic, molecular and functional diversity in vitro. Nature – CNIO Cancer Symposium on Frontiers in Tumour Heterogeneity and Plasticity; Madrid, Spain; 27-30 October 2013
  34. Czyż M (Invited Expert): Heterogeneity and plasticity of melanospheres: implications for development of therapeutic strategies. European Cooperation in Science and Technology, COST Action CM1106 2nd Working Group Meeting. Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells; Warsaw, 19-20 September 2013
  35. Pastuszko A, Kupcewicz B, Czyż M, Małecka M, Budzisz E: Cytotoxic activity of novel half-sandwich organoruthenium(II) complexes. XII International Symposium on Inorganic Biochemistry; Wroclaw; 28 August–1 September 2013
  36. Duchler M, Pęczek Ł, Żuk K, Zaleśna I, Pluta P, Jeziorski A, Czyż M: Analysis of the immunosuppressive microenvironment in tumor samples from breast cancer patients. 3rd International Cancer Immunotherapy & Immunomonitoring CITIM; Cracow; 22-25 April 2013
  37. Czyż M, Koprowska K, Hartman M, Zaleśna I, Duechler M, Sztiller-Sikorska M: Microenvironment-dependent phenotypic heterogeneity of melanoma cells. Cell Symposia: Hallmarks of Cancer; San Francisco, USA; 29-31 October 2012
  38. Szubert M, Kowalczyk-Amico K, Szuławska A, Duechler M, Czyż M, Suzin J: Angiogenesis and inflammatory response in endometriosis – the role of danazol treatment. 15th World Congress of Gynecological Endocrinology; Firenze, Italy; 7-10 March 2012
  39. Szubert M, Duechler M, Szuławska A, Suzin J, Czyż M, Kowalczyk-Amico K: Biomarkers of angiogenesis and inflammatory response in peritoneal fluid of women with endometriosis. 5th World Congress of Gynecological Endocrinology; Firenze, Italia; 7-10 March 2012; Giornale Italiano Ostetricia Ginecologia 34: 321-322
  40. Koprowska K, Jakubowska J, Sztiller-Sikorska M, Czyż M: Parthenolide enhances the anti-tumor efficacy of dacarbazine and temozolomide in melanoma cells with cancer stem cells properties. FEBS Advanced Lecture Course on Translational Cancer Research; Portugal; 27 September-4 October 2011
  41. Czyż M (Invited Speaker): Reversible phenotypic heterogeneity among melanoma stem-like cells. The 5th Polish-French Conference on Cancer Biology and Therapy; Paris, France; 30 May-1 June 2011
  42. Czyż M, Lesiak-Mieczkowska K, Szuławska-Mroczek A, Woźniak M, Jakubowska J: Targeting constitutive and inducible NF-κB pathway by parthenolide in primary and metastatic melanoma cells. Perspectives in Melanoma XIV; Amsterdam, Netherlands; 17-18 September 2010
  43. Grażul M, Czyż M, Kufelnicki A, Woźniczka M, Budzisz E: Structure, protonation constants and cytotoxic effect of Co(II) and Pd(II) ion complexes with chromone ligand in melanoma cells. ISABC 10, 10th Internacional Symposium on Applied Bioinorganic Chemistry; Debrecen, Hungary; 25-28 September 2009
  44. Koprowska K, Stasiak M, Czyż M: Cell cycle arrest or apoptosis are induced by parthenolide and cisplatin in melanoma cells in vitro. XLIV Annual Meeting of the Polish Biochemical Society; Lodz; 16-19 September 2009; Acta Biochemica Polonica 56: 50
  45. Szuławska-Mroczek A, Woźniak M, Lesiak K, Czyż M: Effects of parthenolide and cisplatin on the NFκB-binding activity and expression of NFκB-dependent genes in melanoma cells. XLIV Annual Meeting of the Polish Biochemical Society; Lodz; 16-19 September 2009; Acta Biochemica Polonica 56: 51
  46. Lesiak K, Zaleśna I, Nejc D, Czyż M: Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anti-cancer activity against human melanoma cells in vitro. XLIV Annual Meeting of the Polish Biochemical Society; Lodz; 16–19 September 2009; Acta Biochemica Polonica 56: 50
  47. Jakubowska J, Sztiller-Sikorska M, Woźniak M, Stasiak M, Czyż M: Similarities between pharmacologically induced differentiation of K562 cells and normal erythropoiesis. XLIV Annual Meeting of the Polish Biochemical Society; Lodz; 16–19 September 2009; Acta Biochemica Polonica 56: 109
  48. Sztiller-Sikorska M, Jakubowska J, Stasiak M, Czyż M: Caspase-3 is involved in chemically induced erythroid differentiation of K562 cell line. The Congress of Biochemistry and Cell Biology, 43rd Meeting of the Polish Biochemical Society and 10th Conference of the Polish Cell Biology Society; Olsztyn; 7-11 September 2008; Acta Biochemica Polonica 55: 76
  49. Jakubowska J, Stasiak M, Sztiller-Sikorska M, Czyż M: Combined effects of STI571 and doxorubicin on growth, differentiation and apoptosis of K562 cell line. Apoptosis World 2008 – From mechanisms to applications; Luxembourg; 23-26 January 2008
  50. Lesiak K, Duchler M, Czyż M: NF-κB inhibitors as novel approach against malignant melanoma. Apoptosis World 2008 – From mechanisms to applications; Luxembourg; 23-26 January 2008
  51. Czyż M, Jakubowska [Arkusińska] J, Stasiak M, Szuławska A: Cooperative effects of STI571 (imatinib) and doxorubicin in promoting erythroid differentiation and apoptosis in CML cell line K562. 42nd Meeting of the Polish Biochemical Society; Szczecin; 18-21 September 2007; Acta Biochemica Polonica 54: 51-52
  52. Jakubowska [Arkusińska] J, Stasiak M, Benarek A, Czyż M: STI571 (imatinib) and doxorubicin induction of erythroid differentiation and apoptosis in CML cell line K562 is accompanied by dissipation. 42nd Meeting of the Polish Biochemical Society; Szczecin; 18-21 September 2007; Acta Biochemica Polonica 54: 151
  53. Lewandowska U, Płuciennik E, Czyż M, Hrabec E, Bednarek A: The role of WWOX normal and pathological cell metabolism. 42nd Meeting of the Polish Biochemical Society; Szczecin; 18-21 September 2007; Acta Biochemica Polonica 54: 53
  54. Czyż M, Jakubowska J, Stasiak M, Szuławska A: Combinatorial effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell like K562. BIT's 5th Anniversary Congress of International Drug Discovery Science and Technology (IDDST); Shanghai, China; 28 May-5 June 2007
  55. Duechler M, Stańczyk M, Czyż M, Stępnik M: Parthenolide and buthionine sulfoximine potentiate cytotoxicity of arsenic trioxide. BIT's 5th Anniversary Congress of International Drug Discovery Science and Technology (IDDST); Shanghai, China; 28 May-5 June 2007
Podziel się